Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10862MR)

This product GTTS-WQ10862MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10862MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8450MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ11499MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ10609MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ15351MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ5370MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ10510MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ2268MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ13410MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW